Conversation: Driving Equity and Diversity in Health Tech Investing and Development
Learn about diversity and inclusion best practices in investing from a founder and investor perspective. Tools for venture capitalists to put into place for funding will be discussed. Hear about experiences and challenges of an investor looking for businesses to fund and a startup looking for support and financing. The speakers will share their experiences working to improve equity to influence the types of products and services that are created as well as building a diverse team working to help people from low income backgrounds.
This course was originally recorded in June 2021 as a part of Sepsis Tech & Innovation.
Industry leaders, Public Policy Experts, Health and hospital Leadership (C-Suite, physicians, nurses, pharmacists, CIOs), Health quality and decision support leaders, Health Investors and VCs, Health and Technology Media, Health Advocates, Health Advisors, Health Educators, Health Marketers.
Uriridiakoghene "Ulili" Onovakpuri, MBA
Partner, Kapor Capital
Uriridiakoghene “Ulili” Onovakpuri is a partner at Kapor Capital, an Oakland-based, early stage social impact venture capital firm. She is focused on sourcing investment opportunities, conducting diligence and supporting Kapor Capital’s portfolio companies particularly those in the digital health and medical technology industries. She received her MBA with a concentration in Health sector management from Duke University's Fuqua School of Business. She is a native San Franciscan and a proud UC Berkeley Alum.
Sebastian Seiguer, JD, MBA
Chief Executive Officer & Co-Founder, emocha Health
Sebastian Seiguer (CEO) co-founded emocha with Dr. Robert Bollinger and several other adherence experts at Johns Hopkins in 2014. emocha partners with health plans, health systems, employers and public health departments across the country to support patients at every dose through a Digital Medication Adherence Program. Sebastian has led emocha to become the leading platform for video Directly Observed Therapy in the United States with over 100 customers spanning the healthcare landscape. Sebastian serves as Primary Investigator on 3 NIH medication adherence research grants (tuberculosis, addiction, transplant) and is a National Institute on Drug Abuse (NIDA) Innovation Grant Reviewer.
No continuing education credits are offered for this session.
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.